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Safety and efficacy of patient specific intramuscular
injection of HGF plasmid gene therapy on limb
perfusion and wound healing in patients with
ischemic lower extremity ulceration: Results of the
HGF-0205 trial
Richard J. Powell, MD,a Phillip Goodney, MD,a Farrell O. Mendelsohn, MD,b Elaine K. Moen, MD,c
and Brian H. Annex, MD,d for the HGF-0205 Trial Investigators, Lebanon, NH; Birmingham, Ala;
Indianapolis, Ind; and Charlottesville, Va
Objectives: We have previously reported the results of a dose-finding phase II trial showing that HGF angiogenic gene
therapy can increase TcPO2 compared with placebo in patients with critical limb ischemia (CLI). The purpose of this
randomized placebo controlled multi-center trial was to further assess the safety and clinical efficacy of a modified HGF
gene delivery technique in patients with CLI and no revascularization options.
Methods: Patients with lower extremity ischemic tissue loss (Rutherford 5 and 6) received three sets of eight intramuscular
injections every 2 weeks of HGF plasmid under duplex ultrasound guidance. Injection locations were individualized for each
patient based on arteriographically defined vascular anatomy. Primary safety end point was incidence of adverse events (AE) or
serious adverse events (SAE). Clinical end points included change from baseline in toe brachial index (TBI), rest pain
assessment by a 10 cm visual analogue scale (VAS) as well as wound healing, amputation, and survival at 3 and 6 months.
Results: Randomization ratio was 3:1 HGF (n  21) vs placebo (n  6). Mean age was 76  2 years, with 56% male and
59% diabetic. There was no difference in demographics between groups. There was no difference in AEs or SAEs, which
consisted mostly of transient injection site discomfort, worsening of CLI, and intercurrent illnesses. Change in TBI
significantly improved from baseline at 6 months in the HGF-treated group compared with placebo (0.05  0.05 vs
0.17 0.04; P .047). Change in VAS from baseline at 6 months was also significantly improved in the HGF-treated
group compared with placebo (1.9  1.3 vs 0.06  0.2; P  .04). Complete ulcer healing at 12 months occurred in
31% of the HGF group and 0% of the placebo (P .28) There was no difference in major amputation of the treated limb
(HGF 29% vs placebo 33%) or mortality at 12 months (HGF 19% vs placebo 17%) between groups.
Conclusion:HGF gene therapy using a patient vascular anatomy specific delivery technique appears safe, maintained limb
perfusion, and decreased rest pain in patients with CLI compared with placebo. A larger study to assess the efficacy of this
therapy on more clinically relevant end points is warranted. (J Vasc Surg 2010;52:1525-30.)Critical limb ischemia (CLI) remains a major unmet
public health care need. At present, effective treatment
options for this patient population involve some form of
revascularization, either through endovascular approaches
or bypass surgery. Unfortunately, up to 50% of patients
with CLI are not candidates for revascularization because
of unsuitable anatomy or associated comorbidities such as
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Options for patients who are not candidates for revascular-
ization remain poor, as there is no US Food and Drug
Administration-approvedmedical therapy for CLI. Patients
who do not have the option of revascularization have a 20%
to 40% incidence of major amputation or death within 1
year.2,3 The incidence of CLI is expected to increase over
the course of the next 10 to 15 years.
Therapeutic angiogenesis is a developing biologic ther-
apy that attempts to use various angiogenic growth factors
or autologous stem cells to improve perfusion in areas of
ischemia through the development of new blood vessels
from pre-existing blood vessels. Because of the short half-
life of recombinant proteins, current clinical trials have
approached the delivery of angiogenic factors through ei-
ther a stem cell or gene therapy approach. Stem cell thera-
pies in theUnited States are currently in early development,
whereas several randomized placebo controlled gene ther-
apy trials have been reported.
We have recently reported the results of the intramus-
cular infection of hepatocyte growth factor plasmid to
1525
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emia (HGF-STAT) angiogenic gene therapy trial.4 This
was a placebo-controlled randomized multi-center phase II
trial that assessed the safety of varying doses of human
hepatocyte growth factor (HGF) gene therapy in patients
with CLI. HGF is an angiogenic protein that has been
shown to improve neovascularization and limb perfusion in
animal models of hind limb ischemia.5-7 In addition, this
study evaluated efficacy as determined by change in trans-
cutaneous oxygen pressure (TcPO2) in the foot following
treatment, a surrogate measure for change in limb perfu-
sion. This study showed that HGF gene therapy was well
tolerated and that the high dose gene therapy group had a
significant improvement in TcPO2 from baseline compared
with placebo. Based on the results of the HGF-STAT trial,
we conducted a second follow-up phase II study to further
define the safety and potential efficacy of the HGF gene
therapy dose identified in the previous trial to improve limb
perfusion in patients with CLI. This was done prior to
considering a phase III pivotal trial in order to gain further
safety data. In addition, questions remained after the initial
trial regarding the optimal location and delivery technique
best suited to efficiently deliver the HGF plasmid. The
purpose of the current study was to assess the effect of HGF
gene therapy using a novel patient-specific gene delivery
technique on safety, wound healing, and toe brachial index
(TBI) in patients with CLI.
METHODS
This trial was approved by each study site’s Institu-
tional Investigation Review Board prior to patient enroll-
ment. This was a double-blind, parallel-group, placebo-
controlled multi-institutional study in which eligible
subjects were randomized to receive placebo or 4.0 mg
AMG0001 by intramuscular injection. After a 30-day
screening period, eligible subjects entered a 28-day treat-
ment period during which subjects were dosed on three
separate occasions (Days 0, 14, 28). Following the treat-
ment period, subjects were followed for the next 11
months. The safety analysis was analyzed on intent-to-treat,
which included all randomized subjects who received at
least one dose of treatment. The efficacy evaluable (EE)
population included all subjects who received all three
doses and had at least one follow-up visit after receiving all
three doses but before having either a peripheral vascular
intervention or a major amputation. Eight centers enrolled
patients into the trial.
Injections were performed into the ischemic extremity
based on vascular disease anatomy as depicted on arteriog-
raphy, magnetic resonance angiography, or computed to-
mography angiography and determined by a central com-
mittee of vascular specialists. This gene delivery technique
utilized ultrasound-guided injection into the muscle sur-
rounding occluded tibial vessels based on the preprocedure
arteriography.
The goal of the committee was to ensure that injections
were delivered into regions of the anatomically most severe
vascular disease.8 This resulted in all injections being placedbelow the knee in patients with only tibial occlusive disease
and injections placed above and below the knee in patients
with combined SFA and tibial disease. Each series of injec-
tions consisted of eight injections of 3.0 ml volume deliv-
ered under duplex guidance to confirm intramuscular de-
livery of the therapeutic.
The efficacy end points were defined as wound healing
as measured by change in size of ulcer at months 3 and 6,
along with reduction in major amputation and improved
pain at rest as measured by the visual analogue scale (VAS),
and hemodynamic measurements as measured by ankle-
brachial index (ABI)/TBI at month 3 and month 6. Com-
plete wound healing required complete epithelialization of
the wound for at least 2 weeks. Complete wound healing in
patients with gangrene involving the toes, as shown in Fig
1, was defined as healing of the surgical wound following
amputation or excision. Additional study end points in-
cluded survival and quality of life measures.
Major inclusion criteria included:
1. Subjects needed to have appropriately sized ischemic
peripheral ulcer(s) or tissue loss. Photographs of the
wounds were reviewed by a vascular specialist prior to
patient enrollment.
2. Subjects needed to have one or both of the following
hemodynamic indicators of severe peripheral arterial
occlusive disease:
A. Ankle systolic pressure (in either the dorsalis pedis or
posterior tibial arteries) of 70 mm Hg or
B. Toe systolic pressure 50 mm Hg.
3. The subject was a poor candidate for standard revascu-
larization treatment options for peripheral arterial dis-
ease, based on inadequate bypass conduit, unfavorable
anatomy, or poor operative risk.
Major exclusion criteria included:
1. Subjects who, in the opinion of the investigator, had a
vascular disease prognosis that indicated they may re-
quire a major amputation (at or above the ankle) within
4 weeks of start of treatment.
2. Subjects with a diagnosis of Buerger’s disease (throm-
boangitis obliterans).
3. Subjects with hemodynamically significant aorto-iliac
occlusive disease.
4. Subjects who have had a revascularization procedure
within 12 weeks prior to treatment initiation that re-
mained patent. Revascularization procedures that were
evidenced to have failed (completely occluded) for 2
weeks prior to treatment initiation were acceptable.
5. Subjects with deep ulcerations with bone or tendon
exposure, or clinical evidence of invasive infection (eg,
cellulitis, osteomyelitis, etc) uncontrollable by antibiotic
therapy.
6. Evidence or history of malignant neoplasm (clinical,
laboratory, or imaging), except for fully resolved basal
cell carcinoma of the skin. Patients who underwent
successful tumor resection or radio-chemotherapy of
breast cancer more than 10 years prior to inclusion in
in two
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the study. Patients who had successful tumor resection
or radio-chemotherapy of all other tumor types more
than 5 years prior to inclusion in the study, and with no
recurrence, could be enrolled in the study.
7. Subjects who had proliferative diabetic retinopathy, se-
vere non-proliferative retinopathy, recent (within 6
months) retinal vein occlusion, macular degeneration
with choroidal neovascularization, macular edema on
fundus evaluation by ophthalmologist, or intraocular
surgery within 3 months.
8. Subjects with history of end stage renal disease (ESRD)
defined as significant renal dysfunction evidenced by a
creatinine of 2.5 mg/dL, or receiving chronic hemo-
dialysis therapy.
Statistical plan. The sample size planned for this
study was a maximum of 48 randomized subjects, with 32
subjects randomized to the AMG0001 arm and 16 subjects
randomized to the placebo arm. Allowing for subjects who
prematurely discontinued or were excluded from the effi-
cacy evaluable population, it was expected that there would
be at least 39 evaluable subjects (26 in the AMG0001 arm
and 13 in the placebo arm) at the month 3 follow-up visit.
This latter number is considered appropriate to determine a
statistically significant difference in the reduction of total
wound area between the AMG0001 treatment group and
the placebo treatment group at month 3.
A Japanese study with the same AMG0001 dosage
and administration methods showed a mean reduction in
total wound area of 2.5 cm2 at month 3 compared with
Fig 1. Example of severity of tissue lossbaseline in the AMG0001-treated arm.8 Standard devi-ation estimates for these means ranged from 1.05
(AMG0001) to 4.7 (placebo). Assuming the common
standard deviation was 3.0, the proposed sample size
would provide sufficient power (80%) at an alpha  0.05
level to detect a minimum mean difference in total
wound area of 2.9 cm2 from baseline to month 3 be-
tween the subjects in the AMG0001-treated arm and the
subjects in the placebo-treated arm.
Analyses for continuous variables were performed with
t tests, and analyses for categorical variables were performed
with Fisher’s exact tests. P .05 was considered significant.
For missing data, last observation carried forward (LOCF)
was used in the analysis.
RESULTS
Demographics. The trial was stopped early after en-
patients enrolled into HGF-0205 Trial.
Table. Patient characteristics
Placebo
(n  6)
HGF-treated
(n  21) P value
Age 78  2 years 76  2 years .64
Race
White 5 (83%) 18 (86%) 1.0
Black 1 (17%) 3 (14%)
Gender
Male 2 (33%) 13 (62%) .36
Tobacco 3 (50%) 14 (67%)
Diabetes 3 (50%) 13 (62%) .66
Creatinine clearance
60 ml/min 4 (67%) 12 (57%) 1.0rolling 27 subjects that were randomized to either HGF
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ics were not different between the groups and are shown in
the Table. All patients in the HGF-treated group had
undergone either a failed open surgical revascularization
(85%) and or endovascular therapy (24%). In the placebo-
treated group, surgical revascularization had been per-
formed in 67% of subjects and endovascular therapy in 17%.
Prior to enrollment, major contralateral amputation had
been performed in 14% of HGF-treated patients com-
pared with 0% of placebo (P 1.0). Minor amputation had
been performed in 29% of HGF-treated subjects compared
with 0% of placebo (P  .28).
Safety. The injections were well-tolerated. There was
no difference in adverse or serious adverse events between
the two groups at 12-month follow-up. Adverse events
occurred in 95% of HGF-treated subjects and 83% of
placebo-treated subjects (P .40). The majority of adverse
events consisted mostly of transient injection site discom-
fort, worsening of CLI, and intercurrent illnesses. There
was no progression of diabetic retinopathy, and no patients
developed new malignancy during follow-up.
Wound healing. At 6-month follow-up, wounds had
healed in 19% of patients in the HGF group compared with
0% in the placebo group. This was not a significant differ-
ence. By 12 months, 31% of patients had wounds healed in
the HGF group compared with 0% in the placebo group
(P  .28). There was no significant difference in rate of
wound healing between the groups at any time point
studied.
TBI. As shown in Fig 2, change in TBI from baseline
in the HGF-treated patients was significantly improved at 6
months compared with placebo. The TBI in HGF-treated
patients increased 0.05 0.05 compared with a decrease in
TBI of 0.17  0.04 in placebo-treated patients (P 
.047).
Lower extremity pain. As shown in Fig 3, pain, as
measured by VAS, was significantly improved from baseline
at 6 months in HGF-treated patients compared with pla-
cebo. VAS improved (decreased) from baseline at 6 months
Fig 2. Toe brachial index at baseline and 3 and 6 months follow-
ing first injections (solid columns) compared with placebo (hatched
columns). Data presented as mean  standard error.in the HGF-treated group compared with a worsening(increase in VAS) in placebo (1.9 1.3HGF vs0.06
0.2 placebo; P  .04).
Amputation and survival. There was no difference in
major amputation of the treated limb (HGF 29% vs placebo
33%) or mortality (HGF 19% vs placebo 17%) at 12months
between groups. There was no difference in minor ampu-
tation between the groups.
DISCUSSION
There is currently noUS Food andDrug Administration-
approved medical therapy for CLI. Therapies currently
employed to treat CLI include endovascular therapy, open
surgical revascularization, and primary amputation. Both
open surgery and endovascular therapy are effective revas-
cularization strategies.1,9,10 Unfortunately, endovascular
options are frequently limited in this patient population
due to the extent of occlusive disease, which frequently
occurs in the distal femoral-popliteal and tibial segment and
often presents as total occlusions. As shown in the Bypass
versus Angioplasty in Severe Ischaemia of the Leg (BASIL)
trial, open surgical options were not available in up to 50%
of patients with CLI due to associated medical comorbidi-
ties, lack of suitable autogenous conduit, or distal target
vessel.1 In the absence of acceptable endovascular or surgi-
cal therapy, patients frequently require major amputation
to control pain or infection. Therefore, there remains a dire
need for a less invasive medical therapy to treat patients
with CLI.
Prior studies that attempted to utilize angiogenic gene
therapy to treat claudication have met with disappointing
results. Numerous randomized placebo-controlled claudi-
cation trials using various VEGF isoforms, FGF, and hyp-
oxia inducible factor-1 alpha have failed to show a clinically
meaningful improvement in peak walking time compared
with placebo-treated subjects.11,12
However, unlike claudication, clinical trials using an-
giogenic gene therapy to treat CLI have been met with
Fig 3. Pain measured as visual analogue scale (VAS) at baseline
and 3 and 6 months following first injections (solid columns)
compared with placebo (hatched columns). Data presented as
mean  standard error.somewhat more promising results. A recent randomized
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FGF-1, the Talisman 201 Trial, has been completed and
has shown an improved major amputation-free survival in
FGF-1-treated subjects compared with controls.13 In this
trial, 12-month amputation-free survival was 73% in the
FGF-treated subjects compared with 48% in the subjects
receiving placebo. In a subsequent study, these investiga-
tors have gone on to show proof of plasmid uptake and
protein expression by muscle cells in the region of FGF
plasmid injection by studying tissues from patients treated
with FGF plasmid prior to lower extremity amputation.14
The results of the current study support the concept
that HGF gene therapy can improve limb perfusion in
patients with CLI with tissue loss. HGF gene therapy
resulted in improved TBI and decreased rest pain when
compared with subjects treated with placebo. These find-
ings are in line with those reported from the HGF-STAT
trial, which demonstrated an increase in TcPO2 from base-
line in patients treated with high-dose HGF gene therapy
compared with placebo. In the current study, there was no
difference in major amputation between subjects treated
with HGF gene therapy or placebo. This was not surprising
for two reasons. First, given that our goal was to demon-
strate safety and efficacy of the HGF plasmid therapy, the
study was not powered to identify differences in an infre-
quent end-stage outcome measure such as major amputa-
tion. Second, the extent of tissue necrosis present in the
CLI patient population was highly variable, as many pa-
tients had extensive tissue loss, an example of which is
shown in Fig 1. Because of the variation in tissue loss at
presentation, it was not surprising that there was no differ-
ence in major amputation between the groups.
A recent study completed in Japan using HGF gene
therapy to treat patients with relatively small ischemic
ulcers was stopped early by the Data Safety Monitoring
Board. In this trial, patients treated with HGF gene
therapy had a 70% improvement in ulcer healing or rest
pain compared with 30% in subjects treated with place-
bo.8 In summary, these three HGF trials have together
shown an increase in limb perfusion as measured by
TcPO2 and TBI as well as improvements in wound
healing compared with placebo. Furthermore, there have
been no safety concerns. It is important to point out that
these studies have not shown an improvement in the
more clinically meaningful outcome of amputation-free
survival; however, the studies were small-sized and not
powered to show such a difference.
The current phase II trial was stopped early following
an interim analysis at 6 months. The reasons for stopping
the trial early were several. Sufficient numbers of patients
had been enrolled into the study to adequately assess the
safety of the utilized dose of HGF gene therapy to support
a pivotal trial. The purpose of the second phase II trial was
to determine if there was sufficient signal of efficacy to
warrant advancing to a pivotal trial. This does not necessar-
ily require statistical significance in light of previous phase
II trials. In the current trial, there was a signal of efficacy
based on hemodynamic data and wound healing that, whentaken into account with the previous US phase II trial that
showed improved TcPO2 in treated patients and the pre-
viously described Japanese trial, there was sufficient evi-
dence of efficacy to proceed with a pivotal trial. This deci-
sion was also influenced by the difficulty and typically slow
recruitment inherent in conducting CLI gene therapy trials
in no-option CLI patients.
Due to many trial design issues, performing CLI clini-
cal trials using gene therapy remains difficult. The CLI
patient represents a widely disparate population in terms of
both extent of disease, which can range from rest pain to
extensive tissue loss, but also rate of progression of disease.
CLI patients can present with a vast spectrum of wounds
that vary from extensive gangrene and deeply penetrating
heel wounds to mild superficial skin erosions. Because of
this heterogenous patient population, outcomes are more
variable, and, as a result, larger numbers of patients may be
needed to discover proof of efficacy. In addition, despite
our encouraging results in this trial, it remains unlikely that
attempts at limb revascularization using biologic ap-
proaches are going to result in the same level of improved
limb perfusion as a successful lower extremity bypass. In the
future, CLI trials must standardize acceptable initial wound
size and wound care treatments to ensure that study pop-
ulations are homogenous and comparable.
The CLI patient population is associated with a high
prevalence of severe comorbidities and limited life expect-
ancy. In the current study, 93% of patients suffered at least
one adverse event during the course of the study, further
underscoring the extensive nature of vascular disease
present in the CLI cohort.
At present, all CLI studies have enrolled “no-option”
subjects with ischemic ulcers or rest pain. These are patients
in whom all endovascular or open surgical options have
been exhausted or who are too high-risk medically to
undergo revascularization procedures. Gene therapy within
this population may be biased toward failure, as these
patients may be biologically less likely to respond to angio-
genic gene therapy when compared with the general CLI
patient population. In the current trial, 96% of the study
population had undergone at least one failed attempt at
either open surgical revascularization or endovascular ther-
apy prior to enrollment into the trial. In future CLI trials,
consideration should be given to the enrollment of “poor-
option” CLI patients who have a higher risk for revascular-
ization with expected decreased bypass success such as a
synthetic tibial bypass or spliced arm vein graft.
At the present time, amputation-free survival remains
the gold standard end point for a CLI trial (TASC II).15
This particular end point has several shortcomings that
include the lack of any measurable effect on quality of life as
well as the inclusion of death, which is a non-limb-specific
end point. The development of more limb-specific end
points, such as major adverse limb events in end points
proposed by an SVS CLI working group, would help to
better define the role of future therapies for CLI.16
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The current trial has shown that HGF gene therapy is
safe and well tolerated. HGF gene therapy has been shown
to maintain limb perfusion and decrease ischemic rest pain
in patients with CLI. Persistent obstacles exist with current
study designs that complicate the ability to successfully
perform clinical CLI trials. Preliminary trials using HGF
gene therapy are promising, and a larger study address-
ing clinically relevant end points is warranted and being
planned.
We acknowledge the efforts of Julie Vanas and Carol
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